China's SciClone Pharma jumps most on record on upbeat results, buyback plan

SciClone Pharmaceuticals (Holdings)

25/03/2022 05:31

** Shares of oncology and severe infection therapy-focused
SciClone Pharmaceuticals (Holdings) Ltd  6600.HK  jump 16.4% to
HK$8.80, their biggest intraday percentage gain since debut on
March 3, 2021 
    ** Stock hit the highest since Jan 20, on course for a
seventh straight session of gains; the biggest percentage gainer
in the Hang Seng Composite Index  .HSCI  
    ** The China-based firm says its 2021 net profit rose 22.5%
year-on-year to 923.4 mln yuan ($145.19 mln) with revenue
surging 31.3% to 2.52 bln yuan. It declares a final dividend of
HK$0.35 per share  urn:newsml:reuters.com:*:nFWN2VR16N
    ** Co says its board has approved a plan to buy back shares
in the open market and its financial position is solid and
healthy (https://bit.ly/3IKR7ny)
    ** The Hang Seng Commerce & Industry Index  .HSNC  drops
2.9% and Hong Kong's healthcare index  .HSCIH  plunges 5%
    ** The Hang Seng Composite Index  .HSCI  falls 1.9% and the
benchmark Hang Seng Index  .HSI  declines 1.7%
    
     ($1 = 6.3601 Chinese yuan)

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))